Vanderbilt trial tests intrathecal cytarabine for ICANS after CAR T; Gilead is collaborator

One item posted this week involves Gilead as a collaborator on an academic-sponsored trial.

• The "Lazarus Trial" (NCT07763210), sponsored by Vanderbilt-Ingram Cancer Center with Gilead Sciences listed as collaborator, is a Phase 2 study of intrathecal cytarabine and hydrocortisone given early for immune effector cell associated neurotoxicity syndrome (ICANS) following CD19 CAR T therapy, including axi-cel and brexu-cel, in relapsed or refractory non-Hodgkin lymphoma. The study is recruiting, with an actual start date of September 25, 2026¹, and enrollment is estimated at 59 participants¹. The primary goal is to reduce ICANS duration and the incidence of grade 3 or greater ICANS compared with historical experience¹, with patients receiving 100 mg IT with onset of grade 1/2 ICANS¹ for the trial drugs.